Secondary Malignant Neoplasm — Trials

Secondary Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

14,658 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,270
Recruiting: 2,317
Ph III recruiting: 269
Growth YoY: +13.3%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,960)

clinicaltrialsPublishedShowing 1–50 of 1,223 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03412877	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	recruiting	Phase 2	285	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT04086485	Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)	recruiting	Phase 1 / Phase 2	56	National Cancer Institute (NCI)NIH	1	Sep 28, 2026